The article argues that AI’s success in molecular design won’t cure most diseases without a deeper understanding of human biology and disease mechanisms. It calls for large-scale, causal biological measurements and better links between cellular data and clinical outcomes before AI can deliver truly transformative medicines.

• AI drug discovery has focused on molecule design, but the real bottleneck is upstream: most diseases lack a validated biological target to hit.
• 90% of clinical trials fail because they target the wrong biological mechanism, not because molecule design is too slow.
• Genuinely new drug targets have dropped from ~100 in 2015 to ~30 in 2024, while 38 targets each now have 50+ drug programs piling onto the same well-known locks.
• Fixing this requires massive causal/perturbational biology data (billions more measured cell states), not just better AI models, since current cell atlases barely scratch the surface.

Anthropic has kicked off an internal drug discovery effort focused on neglected diseases to sharpen its AI tools for biopharma clients. By running its own research alongside partners, the company aims to gather feedback and demonstrate Claude Science’s capabilities.

• Anthropic is running its own internal drug discovery program targeting neglected diseases to battle-test and improve Claude Science before selling it to pharma partners.
• As a public benefit company, Anthropic claims it can choose projects based on patient need rather than commercial potential, unlike typical biotechs.
• The company hasn't said what happens if it finds a promising drug candidate, leaving unclear how it would handle clinical trials.
• This follows a mixed track record for big tech in healthcare, including Alphabet's life sciences unit, Apple's health features, and Amazon's One Medical/PillPack acquisitions.

The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

• Drug candidate pipelines have doubled in the past decade but novel FDA approvals stayed flat at ~50/year, proving clinical development—not discovery—is the real bottleneck.
• Preclinical assets license for tens of millions, but value jumps to hundreds of millions or low-billions post-Phase 2 proof of concept—a premium set to shrink as AI floods the pipeline with candidates.
• Competition per target is already intense (100+ programs on targets like PD-1/GLP-1) and could double or triple by 2030, making individual molecules less rare and pushing investors to demand better translational data and trial design.
• AI excels at data-rich, fast-feedback problems (virtual screening, protein folding) but struggles with messy, high-variability clinical questions (endpoint selection, immune response prediction, adaptive trials)—so real value will shift to whoever masters those still-slow areas.

This post lists nine key quotes from a San Francisco talk by Demis Hassabis and Sebastian Mallaby covering everything from OpenAI’s 50% bankruptcy risk to the need for new “AlphaFold” moments in drug discovery. They debate AGI probabilities, frontier cyber defense access, global AI optimism, and the economic and philosophical challenges of a post-scarcity future.

• Mallaby puts a 50% chance OpenAI goes bankrupt within 18 months
• Hassabis says six more AlphaFold-level breakthroughs are needed to cut drug-delivery timelines from 10 years to months
• Hassabis calls the idea that p(doom) is zero "crazy," acknowledging real existential risk from AI
• Hassabis argues economists, social scientists, and philosophers must join scientists in shaping decisions about how AI's value gets shared

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

• AWS launched Amazon Bio Discovery, a no-code AI platform letting scientists run drug-design workflows using foundation models plus an AI agent, cutting months of research into weeks.
• In a Memorial Sloan Kettering/Twist Bioscience collaboration, nearly 300,000 AI-designed antibodies were narrowed to 100,000 for physical lab testing.
• Bayer, Broad Institute and Voyager Therapeutics are early adopters, and 19 of the top 20 global pharma companies already use AWS cloud services.
• AWS is separately partnering with Boston Consulting Group and Merck on an AI tool to improve clinical trial site selection.